Treatment Advances

November 20, 2024

If you are an adult with relapsed/refractory precursor B-cell ALL, learn how a new FDA-approved CAR T-cell therapy may be a treatment option for you.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

November 01, 2024

Learn about how VNX-101 can help ALL patients that are CD19 positive.

November 01, 2024

Learn how a new treatment option for acute lymphocytic leukemia, a CAR T therapy called obe-cel, can be an effective treatment.

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.

October 22, 2024

Learn how venetoclax and decitabine helped a higher percentage of senior AML patients achieve a complete reduction in AML signs/symptoms and reach transplant.

October 04, 2024

What is the NPM1 mutation in acute myeloid leukemia (AML)? How common is it and how is it treated? Learn answers to these questions!

October 04, 2024

What are natural killer cells? Why do they stop killing chronic lymphocytic leukemia (CLL) cells? What can potentially fix this?

September 17, 2024

Learn why the FDA requested another trial for Iomab-B and what this means for AML patients seeking new treatment options.

September 06, 2024

Revumenib gains FDA Priority Review for treating relapsed KMT2A-rearranged leukemia, with a decision expected by September 26, 2024.